Shares of Sanofi SA (NYSE:SNY) have been assigned a consensus recommendation of “Buy” from the seventeen brokerages that are presently covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $52.50.

Several equities analysts have recently weighed in on SNY shares. UBS Group reissued a “neutral” rating on shares of Sanofi in a research report on Friday, November 30th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Tuesday, December 4th. Jefferies Financial Group upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, December 11th. Morgan Stanley assumed coverage on Sanofi in a report on Friday, December 14th. They set an “equal weight” rating for the company. Finally, Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Friday, January 18th.

In related news, major shareholder Sanofi sold 131,115 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.00% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its holdings in shares of Sanofi by 10.8% in the 4th quarter. Geode Capital Management LLC now owns 56,590 shares of the company’s stock worth $2,456,000 after buying an additional 5,525 shares during the period. FMR LLC lifted its holdings in shares of Sanofi by 6.2% in the 4th quarter. FMR LLC now owns 9,057,978 shares of the company’s stock worth $393,207,000 after buying an additional 529,995 shares during the period. Aspire Private Capital LLC purchased a new stake in shares of Sanofi in the 4th quarter worth $149,000. Global Retirement Partners LLC lifted its holdings in shares of Sanofi by 420.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,040 shares of the company’s stock worth $45,000 after buying an additional 840 shares during the period. Finally, Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in shares of Sanofi by 10.0% in the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 22,467,022 shares of the company’s stock worth $975,294,000 after buying an additional 2,039,820 shares during the period. Institutional investors and hedge funds own 7.04% of the company’s stock.

NYSE SNY opened at $45.09 on Thursday. The company has a market cap of $113.09 billion, a PE ratio of 14.41, a P/E/G ratio of 2.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. Sanofi has a fifty-two week low of $37.43 and a fifty-two week high of $45.62.

Sanofi (NYSE:SNY) last released its earnings results on Thursday, February 7th. The company reported $0.63 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.01. The firm had revenue of $9 billion for the quarter, compared to the consensus estimate of $9 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS. On average, equities analysts expect that Sanofi will post 3.1 earnings per share for the current year.

The firm also recently disclosed an annual dividend, which will be paid on Friday, May 31st. Investors of record on Wednesday, May 8th will be issued a dividend of $1.7395 per share. This represents a yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. Sanofi’s payout ratio is currently 38.34%.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: Understanding the different types of bonds

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.